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Abstract
Background: Dyslipidemia is commonly seen in human immunodeficiency virus (HIV) infected patients. Understanding
the risk factors of abnormal lipid profiles is urgent for proposing targeted approaches to prevention. Our objective was to
assess the incidence and associated factors of abnormal lipid profiles and atherogenic index of plasma (AIP)
among antiretroviral therapy (ART) naïve men who have sex with men (MSM) acute HIV infection (AHI) and
chronic HIV infection (CHI) patients in China.
Methods: We compared lipids parameters such as triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and AIP between MSM HIV-infected patients and MSM
HIV negative controls. Multivariable linear regression was used to evaluate risk factors of higher AIP.
Results: We performed a case control analysis of 110 AHI, 110 CHI and 100 HIV negative MSM participants. The TC,
HDL-C and LDL-C levels were decreased in the AHI and CHI groups compared to the controls (3.90 ± 0.73 mmol/L
and 3.72 ± 0.74 mmol/L versus 4.49 ± 0.91 mmol/L, p < 0.001; 1.00 ± 0.25 mmol/L and 1.01 ± 0.30 mmol/L versus 1.19 ±
0.29 mmol/L, p < 0.001; 2.11 ± 0.57 mmol/L and 2.22 ± 0.58 mmol/L versus 2.75 ± 0.78 mmol/L, p < 0.001). The AIP score
was higher in the AHI patients compared to the control group [0.08 (−0.05–0.20) versus−0.04 (−0.21–0.22), p = 0.039]. In
total groups, AIP was associated with AHI and TG positively (β = 0.029 ± 0.012, p = 0.015;β = 0.273 ± 0.009, p < 0.001) and
correlated with HDL-C inversely (β = -0.444 ± 0.023, p < 0.001).
Conclusions: HIV infection contributed to decreased TC, LDL-C and HDL-C. AHI contributed to higher AIP level. An
urgent need exists for earlier HIV diagnosis and better prevention of dyslipidemia in China.
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Background
As a kind of metabolic abnormalities, dyslipidemia has
been of significant concern among human immunodefi-
ciency virus (HIV) infected patients [1–3]. HIV-infected
adults with lipids perturbations may be at risk of acceler-
ated atherosclerosis and cardiovascular disease [4]. Vari-
ous lipid abnormalities have been recorded in HIV
patients with antiretroviral therapy (ART), particularly
those on protease inhibitors based regimes [5, 6]. The
dyslipidemia associated with ART is manifested as in-
creased trigylcerides (TG), low-density lipoprotein chol-
esterol (LDL-C), total cholesterol (TC) and lower high-
density lipoprotein cholesterol (HDL-C) typically [7, 8].
Recently, the effect of HIV itself has been proposed as
a contributor to lipid abnormalities. HIV infection may
lead to structural and functional changes in HDL-C [9].
In both ART‑naïve chronic HIV infection (CHI) adult
and children patients, low HDL-C was the most fre-
quently observed abnormality and there existed a signifi-
cant relationship between lipid parameters and viral load
[10, 11]. Results from the Veterans Aging Cohort Study
showed that HIV infection was associated with de-
creased TC, HDL-C, LDL-C and elevation of TG, ART
initiation did not reverse alteration in TG or LDL-C to
pre-HIV infection levels [12]. This suggests that HIV in-
fection may influence lipids regardless of ART status.
Furthermore, experiment in vitro demonstrated that the
high viremia levels of acute HIV infection (AHI) im-
paired cholesterol efflux capacity, which indicated that
dyslipidemia may occur very early [13].
However, relying solely on single lipid parameter is not
sufficient for evaluating lipid metabolism. Attentions
should be paid to more sensitive indexes. The athero-
genic index of plasma (AIP) [log(TG/HDL-C)], which
correlates well with the size of HDL-C and LDL-C parti-
cles, reflects the presence of atherogenic small particles
accurately [14]. AIP is scarcely taken into consideration
in studies which investigating lipid profiles in HIV pa-
tients. In recent years, men who have sex with men
(MSM) have been a major core risk population for HIV
epidemic in China [15]. Moreover, some traditional risk
factors for dyslipidemia such as smoking, alcohol, abnor-
mal nutritional status, and recreational drug use were
more likely to be prevalent among MSM [16, 17]. Thus,
we hypothesize that the proportion of abnormal lipid
profiles in ART‑naïve MSM HIV patients in China is
high and may occur very early.
Therefore, we investigated the condition of lipid me-
tabolism and AIP among AHI and CHI ART-naïve
MSM populations in China without the confounding
factor of ART with a well matched HIV negative MSM
group. Furthermore, we aimed to investigate the contri-
bution of HIV to lipid abnormalities and associated fac-
tors influencing AIP in ART-naïve patients in China.
Methods
Study design and participants
This was a cross‑sectional study carried out at the ac-
quired immune deficiency syndrome (AIDS) clinical care
centre of The First Affiliated Hospital of China Medical
University and the Beijing You’An Hospital from January
2013 to June 2015 consecutively. Every 4–8 weeks, 6 000
individuals from the HIV primary open cohort in Beijing
and 1650 volunteers recruited from the Rainbow Harbor
voluntary counseling and testing (VCT) Center in the
First Affiliated Hospital of China Medical University in
Shenyang were tested for AHI. The plasmas were col-
lected and tested for HIV antibodies and HIV viral load.
Participants were classified as AHI who met 1 of 2 cri-
teria: (1) had negative or uncertain HIV serology with
HIV RNA more than 10,000 copies/ml or (2) had a posi-
tive HIV serology with evidence of negative testing in
the previous 6 months. Other volunteers who were HIV
negative were invited in the control group (no-HIV
group). The inclusion criteria for the no-HIV group were
(a) male, self-reporting anal intercourse with male part-
ners in the past 1 year, (b) aged 18 years or older. Eligi-
bility criterion for the CHI group was positive HIV
antibody confirmed by Western blot test for more than
6 months.
Exclusion criteria for the three groups were suffering
with severe respiratory failure, kidney failure, heart failure
(New York class III or IV), chronic alcoholism, cachexia
status, diabetes, taking medicines of steroid hormones or
lipid-lowing drugs at the study recruitment period. The
study was approved by the Ethics Committee of the First
Affiliated Hospital of China Medical University and the
Beijing You’An Hospital. All participants provided written
informed consent before attending this study.
Data collection
Data regarding sociodemographic characteristics, includ-
ing gender, age, height, weight, smoking, alcohol con-
sumption were recorded through a interviewer filled
questionnaire which administered face to face in a private
counseling room. The body mass index (BMI) was calcu-
lated using the formula of weight (kg)/height (m2)*10000.
Venous blood was drawn by trained nurses. Serum sam-
ples were tested for HIV antibody screening using a third-
generation enzyme-linked immunosorbent assay. Samples
with positive screening test result were confirmed by HIV-
1/2 Western blot assay. We used the whole blood samples
to determine the counts and percentages of CD4 + T cells
and CD8 + T cells by a FACS Calibur flow cytometer
(Becton-Dickinson, USA). Plasma HIV viral load was
detected by Roche COBAS TaqMan.
The blood pressure was measured by a sphygmomanom-
eter with the patient sitting quietly. The systolic blood pres-
sure (SBP) is equivalent to the value of mercury column
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when hearing the first sound of artery pulse. When the ar-
tery pulse sound decreased or disappeared, the reading of
the mercury column is the value of diastolic blood pressure
(DBP). The blood pressure was measured twice at least
5 min apart. The mean value of two results was recorded.
Hypertension was defined as SBP≧140 mmHg and/or
DBP≧90 mmHg [18].
Fasting blood glucose (FBG) and lipids were measured by
Roche D/P/P modular analysis system using enzymatic
method. Any kind of the abnormal lipid profiles was
defined as dyslipidemia according to the World Health
Organization (WHO) criteria thus hypertriglyceridemia
(TG> 1.7 mmol/L), hypercholesterolemia (TC> 5.2 mmol/L),
low HDL-C (HDL-C < 0.9 mmol/L), high LDL-C (LDL-
C > 3.5 mmol/L), and high TC/HDL-C ratio (>5) [19].
The ratios of TC/HDL-C and AIP were calculated. The
ratio log (TG/HDL-C), which is called AIP, was defined
abnormal when >0.1 [20].
Statistical analysis
All analyses were performed by using SPSS version 18.0
software. Continuous variables were described as mean
and standard deviation (SD) or median and interquartile
range (IQR). Chi‑square test was used to test for the dif-
ference between categorical variables, whereas the differ-
ence between continuous variables was analyzed using
the one way ANOVA as appropriate. Pearson’s correl-
ation coefficient was used to assess the correlations be-
tween AIP and clinical parameters. Univariable linear
regression (enter) was performed to identify variables
predictive of AIP. All variables with p-values < 0.1 were in-
cluded in a multivariable linear regression model to exam-
ine the potential determinants. A two-tailed p-value less
than 0.05 was considered statistically significant.
Results
During the study period, 100 cases of the no-HIV con-
trol group, 110 AHI and 110 CHI patients were enrolled.
Demographic and clinical characteristics of the study
population were summarized in Table 1. The mean age
of AHI group, CHI group and no-HIV control group
were 31.5 ± 8.6, 33.8 ± 6.2 and 32.2 ± 9.0 respectively.
There were no statistically significant differences be-
tween the three groups in terms of age, height, weight,
BMI, SBP, DBP and proportion of smoking, drinking,
hypertension. The mean FBG of the CHI group was sta-
tistically higher than that of the no-HIV control group
and the AHI group (p < 0.05). Compared with the CHI
group, the AHI group had shorter estimated infection
time [65.0 (38.5–106.0) days vs. 631.0 (133.0–1135.0)
days, p < 0.001] and higher CD4 cell counts [404.0 (281.5–
531.5) cell/μl vs. 173.0 (113.3–243.2) cell/μl, p < 0.001].
The viral load level between AHI and CHI groups had no
statistically difference.
The median value and abnormal proportion of TC,
LDL-C of the no-HIV control group were higher than
the other two groups (Table 2 and Fig. 1). The no-HIV
control group had the highest level of HDL-C and the
abnormal proportion of HDL-C of the no-HIV control
group was lower than the other two groups. We found







Age (years) 32.2 ± 9.0 31.5 ± 8.6 33.8 ± 6.2
Height (cm) 174.0 ± 5.1 173.9 ± 4.6 174.5 ± 6.0
Weight (kg) 65.9 ± 11.4 63.9 ± 8.5 66.1 ± 10.9
BMI (kg/m2) 21.8 ± 3.6 21.1 ± 2.6 21.7 ± 3.4
History of smoking, n (%) 38 (38.0) 29 (26.4) 37 (33.6)
History of alcohol, n (%) 45 (45.0) 44 (40.0) 52 (47.3)
SBP (mmHg) 120.0 (114.6–122.7) 114.5 (112.0–120.0) 120.0 (116.0–126.1)
DBP (mmHg) 80.0 (79.0–84.2) 76.0 (72.0–78.2) 83.6 (79.1–88.0)
Hypertension, n (%) 17 (17.0) 10 (9.1) 19 (17.3)
FBG (mmol/L) 4.59 (4.21–5.01) 4.88 (4.47–5.27) 5.13 (4.76–5.53)a
Estimated infection (days) NA 65.0 (38.5–106.0)b 631.0 (133.0–1135.0)
CD4 cell count (cells/mm3) NA 404.0 (281.5–531.5)b 173.0 (113.3–243.2)
HIV RNA
(log10 copies/ml)
NA 4.83 (4.43–5.27) 4.66 (4.27–4.88)
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, n indicates the number of participants, BMI body mass index, SBP
brachial systolic blood pressure, DBP brachial diastolic blood pressure, FBG fasting blood glucose
Data are expressed as mean with ± standard error of mean, geometric mean with 5th and 95th percentile intervals, n or % of n
NA None applicable
ap value < 0.05 between CHI and AHI, CHI and no-HIV
bp value < 0.05 between AHI and CHI
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similar values of TG, TC/HDL-C, proportion of
hypertriglyceridemia, high TC/HDL-C, and dyslipidemia
for the three groups. Compared with the no-HIV control
group, the AHI group had higher AIP score [0.08
(−0.05–0.20) vs.−0.04 (−0.21–0.22), p = 0.039]. There
was no difference in the proportion of abnormal AIP of
the three groups.
Using Pearson’s correlation coefficient, AIP was posi-
tively correlated with TC (p = 0.009), LDL-C (p = 0.014),
weight (p = 0.027), BMI (p = 0.018), DBP (p = 0.045) in
the no-HIV group (Table 3, Model 1). HIV specific sub-
analysis was performed in 220 cases of HIV infected pa-
tients (AHI group and CHI group), we found that weight
(p = 0.001), BMI (p < 0.001) and HIV RNA (p = 0.029)
were positively correlated with AIP (Table 3, Model 2).
Multiple linear regression analysis was carried out to de-
termine the significant predictors of AIP in different
groups (Table 4). In no-HIV control group, AIP was
associated with TG and TC positively (β = 0.245 ±
0.013, p < 0.001;β = 0.039 ± 0.013, p = 0.003) and correlated
with HDL-C inversely (β =−0.413 ± 0.041, p < 0.001). In the
AHI group, significant correlation was noticed between
AIP and TG (β = 0.353 ± 0.010, p < 0.001), HDL-C
(β =−0.417 ± 0.018, p < 0.001). In the CHI group we found
that TG (β = 0.214 ± 0.018, p < 0.001), TC (β = 0.138 ±
0.049, p = 0.006) and LDL-C (β = 0.100 ± 0.048, p = 0.040)
were positively correlated with AIP and significant in-
versely correlation was noticed between AIP and HDL-C
(β =−0.638 ± 0.066, p < 0.001). In total groups, AIP was
associated with AHI and TG positively (β = 0.029 ± 0.012,
p = 0.015;β = 0.273 ± 0.009, p < 0.001 ) and correlated with
HDL-C inversely (β =−0.444 ± 0.023, p < 0.001 ).
Discussion
Our observational study comprehensively compared the
lipid levels and AIP among ART-naïve MSM AHI and







TG (mmol/L) 1.17 (0.76–1.67) 1.11 (0.89–1.52) 1.06 (0.79–1.42)
TC (mmol/L) 4.49 ± 0.91a 3.90 ± 0.73 3.72 ± 0.74
HDL-C (mmol/L) 1.19 ± 0.29a 1.00 ± 0.25 1.01 ± 0.30
LDL-C (mmol/L) 2.75 ± 0.78a 2.11 ± 0.57 2.22 ± 0.58
TC/HDL-C 3.79 (3.18–4.54) 3.95 (3.45–4.57) 3.67 (3.19–4.29)
Hypertriglyceridemia, n (%) 23 (23.0) 17 (15.5) 22 (20.0)
Hypercholesterolemia, n (%) 21 (21.0)a 7 (6.4) 3 (2.7)
Low HDL-C, n (%) 17 (17.0)a 37 (33.6) 44 (40.0)
High LDL-C, n (%) 16 (16.0)a 2 (1.8) 2 (1.8)
High TC/HDL-C ratio, n (%) 16 (16.0) 16 (14.5) 15 (13.6)
Dyslipidemia, n (%) 44 (44.0) 51 (46.4) 52 (47.3)
AIP −0.04 (−0.21–0.22) 0.08 (−0.05–0.20)b 0.03 (−0.17–0.23)
AIP > 0.1, n (%) 38 (38.0) 51 (46.4) 48 (43.6)
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein
cholesterol, LDL-C low-density lipoprotein cholesterol, AIP the atherogenic index of plasma
ap value < 0.05 between no-HIV and AHI, no-HIV and CHI
bp value < 0.05 between no-HIV and AHI
Fig. 1 Incidence of undesirable lipid concentrations among the no-HIV, AHI and CHI group. No-HIV, HIV negative control ; AHI, acute HIV infection
group; CHI, chronic HIV infection group; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; AIP, the atherogenic index of plasma
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CHI patients with a well-matched HIV negative MSM
control group in China. Our study revealed that low
levels of TC, HDL-C and LDL-C occurred in both AHI
and CHI groups. High levels of AIP were prevalent dur-
ing the early stages of HIV-1 infection. The level of TG,
the TC/HDL-C ratio and proportion of dyslipidemia
were, however, similar in all groups. The AIP correlated
with TC, LDL-C, weight, BMI and DBP in MSM control
group and correlated with weight, BMI and HIV RNA in
the HIV infection group. The significant predictors of
AIP were TG, HDL-C and acute HIV infection status.
Our results were similar with other studies which doc-
umented significantly lower levels of TC, HDL-C and
LDL-C cholesterol in treatment-naïve HIV-infected indi-
viduals relative to seronegative controls [21, 22]. Among
all the lipid parameters in treatment-naïve HIV-infected
patients, TG appeared to have an inconsistent report. In
our study, we found that the levels of TG between the
HIV infection group and the control group had no sta-
tistically significant differences. This result was similar
as a previous study [21]. However, Nguemaim NF and
Daniyam CA demonstrated that HIV-infected patients
had significantly lower TC, HDL-C but higher levels of
TG [22, 23]. A possible explanation for the TG differ-
ence may be the differed degrees of immunosuppression
of the HIV infection patients. A study conducted in
Nigeria showed that the TG levels were reversely corre-
lated with CD4 counts and positively correlated with
Table 3 Pearson correlation coefficients between AIP and
clinical and laboratory factors in the no-HIV group (Model 1),
and in the HIV group (Model 2)
Model 1 Model 2*
Factors R P R P
TG (mmol/l) 0.915 <0.001 0.843 <0.001
TC (mmol/l) 0.258 0.009 −0.015 0.821
HDL-C (mmol/l) −0.680 <0.001 −0.653 <0.001
LDL-C (mmol/l) 0.245 0.014 0.021 0.751
FBG (mmol/l) 0.086 0.397 0.049 0.473
Age (years) 0.172 0.087 0.124 0.066
Height (cm) 0.002 0.987 0.001 0.990
Weight (kg) 0.221 0.027 0.219 0.001
BMI (kg/m2) 0.236 0.018 0.233 <0.001
SBP (mmHg) 0.155 0.123 0.095 0.162
DBP (mmHg) 0.201 0.045 0.118 0.082
CD4 cell count (cells/mm3) – – −0.063 0.364
HIV RNA
(log10 copies/ml)
– – 0.151 0.029
Model 2*, AHI and CHI patients were all included
TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, BMI body
mass index, SBP brachial systolic blood pressure, DBP brachial diastolic
blood pressure
Table 4 Factors correlated with AIP after controlling for potential confounders
No-HIV AHI CHI Total*
β ± SE p β ± SE p β ± SE p β ± SE p
AHI versus HIV-negative — — — — — — 0.029 ± 0.012 0.015
CHI versus HIV-negative — — — — — — — —
Age (years) 0.001 ± 0.001 0.322 −0.001 ± 0.001 0.209 −0.001 ± 0.002 0.747 −0.001 ± .001 0.343
Smoker versus nonsmoker −0.004 ± 0.022 0.841 0.009 ± 0.010 0.374 0.020 ± 0.022 0.369 0.013 ± 0.013 0.319
Drinker versus nondrinker 0.009 ± 0.020 0.653 −0.012 ± 0.009 0.177 −0.033 ± 0.022 0.137 −0.011 ± 0.012 0.342
BMI (kg/m2) −0.001 ± 0.003 0.690 0.001 ± 0.002 0.520 0.000 ± 0.003 0.963 0.003 ± 0.002 0.139
TG (mmol/L) 0.245 ± 0.013 <0.001 0.353 ± 0.010 <0.001 0.214 ± 0.018 <0.001 0.273 ± 0.009 <0.001
TC (mmol/L) 0.039 ± 0.013 0.003 — — 0.138 ± 0.049 0.006 — —
HDL-C (mmol/L) −0.413 ± 0.041 <0.001 −0.417 ± 0.018 <0.001 −0.638 ± 0.066 <0.001 −0.444 ± 0.023 <0.001
LDL-C (mmol/L) — — — — 0.100 ± 0.048 0.040 — —
FBG (mmol/L) — — — — — — — —
SBP (mmHg) — — — — — — — —
DBP (mmHg) — — — — — — — —
CD4 cell count (cells/mm3) — — — — — — — —
HIV RNA
(log10 copies/ml)
— — — — — — — —
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, Total*, no-HIV, AHI and CHI participants were all included; BMI body
mass index, TG triglycerides, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose,
SBP brachial systolic blood pressure, DBP brachial diastolic blood pressure
The β values are the multivariate regression unstandardized coefficients
SE, standard error of mean
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viral load [11]. The HIV infected participants in our
study had a better immune status as reflected by a me-
dian CD4 cell count of 404.0 (281.5–531.5) cell/μl in the
AHI group and 173.0 (104.3–243.2) in the CHI group
compared to previous studies. Increased TG tends to
occur with profound immunosuppression. HIV infection
induced a typically early decrease of TC first, followed
by HDL-C and LDL-C, and TG increase last. These
lipids alterations associated with specific changes in im-
mune function [11, 21].
This was the first study that we knew of to report data
on AIP in the acute HIV-infected individuals. The use of
the AIP as an index of dyslipidaemia showed that the
AHI patients were at higher risk of atherosclerosis com-
pared with the MSM control group despite their low
levels of TC and LDL-C. In our study, the AIP values be-
tween CHI group and MSM control group were not sta-
tistically different. Cajetan C. Onyedum’s study showed
that higher AIP was frequent in ART-naïve CHI patients
[24]. However, this study did not have a control group,
and most of enrolled patients were female. Significantly
more females than males had dyslipidemia, which may
contribute to higher AIP value [11, 25]. Our result sug-
gested that the patients in the early HIV infection stage
should be monitored lipids frequently. China is the lar-
gest developing country and the economy develops im-
balanced. Medical resource backwardness exists in
remote areas. In resource limited setting of China, the
AIP is a simple and practical ratio to estimate the risk of
atherosclerosis and cardiovascular disease.
In terms of the relationship between AIP and other
factors, our study showed that the AIP was closely re-
lated with factors such as TC, LDL-C, weight, BMI
and DBP in the MSM group. We also demonstrated a
relationship between AIP and HIV viral load level in
the HIV infection group apart from weight and BMI.
Those who had higher level of HIV RNA had a higher
atherogenic risk profile. This is consistent with the
previously reported studies which showed HDL-C was
negatively correlated with viral load and the TG levels
was positively correlated with viral load on the con-
trary [11, 22, 26]. These studies also demonstrated
AIP or lipids parameters correlated with immunologic
status of HIV infected people. In our study we did not
find the association between AIP and CD4 cell counts
of HIV infected people, further researches about this
should be performed.
The result of multivariable linear regression demon-
strated that acute HIV infection was associated with
higher AIP after controlling for potential confounders.
AHI patients had higher level of HIV viral load which
may result in the increase of AIP. This may have
reflected a direct relationship between viral replication
and chronic inflammation caused by cytokine. The
continuous viral replication induces inflammation and
cytokine secretion such as IFN‑α, which was believed to
make a contribution to increased TG level [27]. Janet
Lo’s study showed that the high magnitude of viremia
characteristic of AHI impaired cholesterol efflux from
macrophages, which could be improved with suppres-
sion of viral replication by ART [13]. We speculate that
suppressing viremia may reduce atherosclerotic risk in
early stage of HIV infection and prospective analyses
with larger sample size should be performed to confirm
this. An urgent need exists for earlier dyslipidemia diag-
nosis and better access to treatment in China.
Strengths of our study include the well matched HIV
negative MSM control group. Most studies used individ-
uals from the general population as the healthy controls,
who might have lifestyles and related risk factors differ
from those of the HIV infected patients. Therefore, to
precisely evaluate the effect of HIV infection on lipids
metabolism and AIP among MSM, it is necessary to use
HIV-negative MSM population as the control group.
Moreover, due to the rising cost and the relative low
HIV testing rate, screening for acute HIV infection is
difficult in China. In this study, acute HIV infection pa-
tients were enrolled based on rigorous criteria.
There were several limitations in our study. First of all,
the sample size of HIV infection group was too small to
show a real difference and detect significant associations
between AIP and other risk factors. Secondly, all the
participants were MSM, our conclusion cannot be ap-
plied to other populations. Thirdly, due to the cross-
sectional design, we could not infer causal relationships
and assess the kinetics of AIP changes.
Despite these limitations, to our knowledge, this is
the first study that investigated AIP among ART-naïve
MSM patients in China and will no doubt stimulate
more research in this field. As a convenient and cheap
method to predict cardiovascular disease risk, AIP is
recommended in China. Life style modification and
prompt treatment are needed to prevent lipids metab-
olism dysfunction. Longitudinal studies are needed to
evaluate the risk of atherosclerosis and cardiovascular
events over time.
Conclusions
Our study revealed that low levels of TC, HDL-C, LDL-
C and high level of AIP were prevalent during the early
stages of HIV-1 infection. The AIP correlated with TC,
LDL-C, weight, BMI and DBP in MSM control group
and correlated with weight, BMI and HIV RNA in the
HIV infection group. The significant predictors of AIP
were TG, HDL-C and acute HIV infection status. Life
style modification and prompt treatment are needed to
prevent lipids metabolism dysfunction.
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